Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV). Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation of the first animal study for the vaccine candidates is expected to begin in May 2020.

Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75 per share, before underwriting discounts and commissions. In addition, Hoth has granted the underwriters a 45-day option to purchase up to an additional 272,727 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Hoth. Gross proceeds from the offering will be approximately $5.0 million. The offering is expected to close on or about May 27, 2020, subject to the satisfaction of customary closing conditions.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the full licensing rights of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up founded by Vincent Njar, the lead scientific inventor, which is developing novel small molecules for the treatment of cancer.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, at Weill Cornell Medicine.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission.

Bright and early Monday morning, Hoth Therapeutics, Inc. (NASDAQ: HOTH) released news that the Company had entered into a joint venture agreement with its joint venture partner, Voltron Therapeutics, Inc., for the “Joint Development for a Self-Assembling Vaccine (SAV) for the Potential Prevention of the Coronavirus (COVID-19).” Most notably, the SAV technology has been exclusively licensed by Hoth’s Joint Venture Partner from Massachusetts General Hospital with “Preclinical development to be undertaken in conjunction with Voltron Therapeutics and the Vaccine & Immunotherapy Center (VIC) at Massachusetts General Hospital.”

Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182 shares of its common stock, at a price to the public of $2.75 per share. The gross proceeds to Hoth from this offering are expected to be approximately $5.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Hoth. In addition, Hoth has granted the underwriters a 45-day option to purchase up to an additional 272,727 shares of common stock at the public offering price, less underwriting discounts and commissions. Hoth intends to use the net proceeds from the offering for general corporate purposes, including the development of products to prevent Coronavirus (COVID-19), working capital, sales and marketing activities, and general and administrative matters.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previously executed sublicense agreement for the compound with Chelexa Biosciences, Inc.

Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 45-day option to purchase up to an additional 15 percent (15%) of the number of shares of common stock sold in the offering solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV). Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation of the first animal study for the vaccine candidates is expected to begin during May of 2020.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö").

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH). The goal of this partnership is to co-develop a new vaccine designed to protect patients at risk of novel coronavirus (COVID-19) infection, leveraging the Self-Assembling Vaccine (SAV) platform developed by the VIC and licensed exclusively to Voltron Therapeutics, Inc. Voltron will spearhead the development along with its joint development partner Hoth.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET. Dr. Poznansky will be providing shareholders with an overview and update on VaxCelerate, a potential vaccine for COVID-19, and answer pre-submitted questions at the conclusion of his prepared remarks. Investors are asked to submit their questions to investorrelations@hoththerapeutics.com .

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19, and could potentially slow its transmission. Dr. Peters is also a recent recipient of COVID-19 Rapid Research Funding sponsored by the Office of the Vice President for Research and Innovation and the C. Kenneth and Dianne Wright Center for Clinical and Translational Research.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET. Dr. Poznansky will be providing shareholders with an overview and update on VaxCelerate, a potential vaccine for COVID-19, and answer pre-submitted questions at the conclusion of his prepared remarks. Investors are asked to submit their questions to investorrelations@hoththerapeutics.com.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership with Zylö Therapeutics, Inc. for topical administration of Anandamide (AEA)-loaded Z-pods™.

HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ: HOTH) (previously released) to advance an application of VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection. Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors. The Company also announced the resignation of current board member, Mr. Anthony Hayes.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest on MSNBC's All In with Chris Hayes last night to discuss COVID-19 vaccines and can be viewed from the following link https://drive.google.com/file/d/1t75xOLeIoIqwHZC8BIhJrrRZl3f1Wqmt/view